Treatment with the ERK1/2 inhibitor U0126 markedly attenuated hyperphosphate-induced cellular hypertrophy in H9c2 myocardial cells.
Hyperphosphate-induced myocardial hypertrophy is mediated by the ERK/NFAT-3 signaling pathway and can be attenuated by ERK inhibition in vitro.
BACKGROUND/AIMS: Numerous epidemiological studies have associated elevated serum phosphorus levels with cardiovascular disease and the risk of death in the general population as well as in chronic kidney disease (CKD) and dialysis patients. In this study, we explored whether elevated phosphate conditions induce cardiac hypertrophy and attempted to identify the molecular and cellular mechanisms in the hypertrophic response. METHODS: H9c2 myocardial cells were incubated in high-phosphate conditions to induce hypertrophy. Pathological hypertrophic responses were measured in terms of cell size, arrangement of actin filaments, and hypertrophy markers such as atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in myocardial cells. Several transcriptional factors involved in cardiac hypertrophy development were measured to investigate the molecular pathways involved in elevated phosphate-induced cardiac hypertrophy. RESULTS: High-phosphate conditions induced cellular hypertrophy, marked by increased cell size, reorganization of actin filaments, and upregulation of both ANP and BNP in H9c2 cells. Both upstream calcineurin and downstream transcription factors, including GATA-4 and NFAT-3, were significantly increased under hyperphosphate conditions. Moreover, both MEK1/2 and ERK1/2 expression increased significantly, and cellular hypertrophy was markedly attenuated by U0126, an ERK1/2 inhibitor. CONCLUSIONS: These results suggest that hyperphosphate conditions induce myocardial hypertrophy through the ERK signaling pathway in H9c2 cells. Our findings provide a link between the hyperphosphate-induced response and the ERK/NFAT-3 signaling pathway that mediates the development of cardiac hypertrophy. In view of the potent and selective activity of the ERK inhibitor U0126, this agent warrants further investigation as a candidate for preventing hyperphosphate-induced cardiac hypertrophy in CKD and dialysis patients.
Liu et al. (Thu,) conducted a other in Myocardial hypertrophy. ERK1/2 inhibitor U0126 vs. High-phosphate conditions alone was evaluated on Cellular hypertrophy (cell size, actin filaments, ANP, BNP). Treatment with the ERK1/2 inhibitor U0126 markedly attenuated hyperphosphate-induced cellular hypertrophy in H9c2 myocardial cells.